



PROGRAM

Sept. 7th

14:00 - 16:00 **Pre-meeting: Biology of renal tumors for clinicians to introduce them to molecular genetics & preclinical techniques** - V. Huff, M. Gessler, E. Pasquier, and others

Coffee Break

16:30 - 18:30 **Current state of clinical research on pediatric renal tumors - why work on their biology?**
Chairs: K. Pritchard Jones & A. Hong

16:30 **History of Wilms tumor clinical research** - J. Dome, Children's National Hospital, Washington, DC, USA & E. Mullen, Dana-Farber / Boston Children's Cancer & Blood Disorders Center, Boston, USA

17:10 **Future clinical challenges: insights from the TME understanding** - as seen by the Young Investigator
B. Dumont, Lyon, France

Patient advocacy for renal tumors:

17:30 **The biology of pediatric renal tumors: A patient/parent perspective** - A. Woods, Children's Oncology Patient Advocacy Committee-member, Children's Cancer Therapy Development Institute, Senior Research Associate, USA

17:50 **How to create a global network for a rare disease: the WAGR experience**
K. Trout, Director, Research & Medical Advocacy International WAGR

18:10 **The Wilms Cancer Foundation, The experience of a patient and a parent** - T.J. Hodgkinson, Canada

18:30 - 19:00 **Roundtable discussion: Patient advocates & researchers working together to accelerate research & improve outcomes**

Sept. 8th

08:00 - 10:00 **Molecular basis of Wilms tumor**
Chairs: M. Gessler & S. Behjati

08:00 **The Little Princess Trust Knowledge Bank of Wilms tumor**
T. Treger, Wellcome Sanger Institute, Hinxton, University of Cambridge

08:40 **Wilms tumor predisposition - What can we learn from familial & bilateral cases?**
J. Wegert, University of Würzburg, Germany

09:10 **The role of structural variation: both 1q gain and CTNNB1/WT1-mutated Wilms tumors show Wnt pathway activation**
P. Kemmeren, Princess Maxima Center, Utrecht, Netherlands

09:35 **DNA methylation patterns, but not genetic sequence alterations, are concordant across multiply sampled sites within individuals with unilateral and bilateral Wilms tumors** - J. Brzezinski, SickKids Hospital, Toronto, Canada

Coffee Break

10:30 - 12:30 **Tumor heterogeneity & Clinical genetics**
Chairs: J. Wegert & V. Huff

10:30 **Caring for children with a genetic predisposition to renal tumors: an evolving landscape**
J. Kamihara, Dana-Farber / Boston Children's Cancer & Blood Disorders Center, Boston, USA

11:10 **Genotype-phenotype correlations in patients with germline WT1-variants in a national cohort**
S. van Peer, Princess Maxima Center, Utrecht, Netherlands

11:30 **Resolving the pathogenesis of treatment-resistant anaplastic Wilms tumors through spatial mapping of cancer cell evolution** - B. Rastegar, Lund, Sweden

11:50 **Anaplastic Wilms tumor cells proliferate despite double stranded DNA breaks and a high burden of copy number aberrations** - K. Uno, Lund, Sweden

12:10 **Features of Wilms Tumors at the Single Cell Transcriptomic Level** - A. Paikari, Würzburg, Germany

Lunch Break & Poster Viewing

14:00 - 15:00 **Keynote lecture**
Chair: E. Mullen & J. Brok

Bridging biology and epidemiology to a global strategy for pediatric renal tumors
K. Pritchard-Jones, President of SIOP and Prof. of Paediatric Oncology at University College London (UCL), Great Ormond Street Institute of Child Health, London, UK

Coffee Break

15:30 - 18:00 **Diagnostics of renal tumors, metastasis and relapse**
Chairs: E. Mullen & J. Brok

15:30 **Possibilities of liquid biopsies in patients with renal tumors**
L. Tytgat, Princess Maxima Center of Pediatric Oncology, Utrecht, Netherlands

16:10 **Recurrent genomic changes associated with relapse in favorable histology Wilms tumor**
S. Gadd, Lurie Children's Hospital, Chicago, USA

16:50 **Inter-Ethnic Variations in Methylation and Spatial Transcriptomics Affecting Local Immune Cell Regulation in Wilms Tumor** - A. Loh, Singapore

17:10 **In search of mutational drivers leading to Wilms tumor recurrence**
D. Perotti, Milano, Italy

17:30 **Differential expression of miRNAs in blood of Wilms Tumor patients at diagnosis**
N. Ludwig, Hamburg, Germany

19:30 **Social Dinner**

Sept. 9th

08:00 - 10:00 **Models for functional understanding of Wilms tumors and drug testing**
Chairs: N. Graf & J. Drost

08:00 **Cell-lineage Crosstalk in Kidney Development and Wilms Tumor**
K. Drake, Nephrology UT Southwestern Medical Center, Dallas, USA

08:40 **Establishment and functional characterization of Wilms tumor organoid cultures**
L. Götz, Würzburg, Germany

09:00 **In vitro compound efficacy and toxicity testing by Organotypic Tissue Slicing in pediatric renal tumors, a novel rapid approach, with potential clinical relevance**
D. Komninos, Princess Maxima Center, Utrecht, Netherlands

09:20 **Identification of Candidate Resistance Mechanisms in Favorable-Histology Wilms Tumor**
A. Fleming, St. Jude Children's Research Hospital, Memphis, USA

09:40 **Functional analysis of Trim28 knockout mouse kidneys**
B. Palhazi, Würzburg, Germany

Coffee Break

10:30 - 12:30 **Non-Wilms tumors**
Chairs: M. vd Heuvel & J. Geller

10:30 **Biology of rhabdoid tumors: perspectives for innovative treatments**
F. Bourdeaut, Institut Curie, Paris, Fr

10:50 **TFE RCC Genomic data from AREN03B2**
J. Geller, CCTST Cincinnati Children's Hospital Medical Center, USA

11:30 **Towards rational epigenetic combination therapy of rhabdoid tumors based on the mechanisms of clinical resistance to EZH2 inhibition in SMARCB1-deficient sarcomas**
A. Kentsis, MSKCC, New York, USA

11:55 **Establishing a pediatric kidney tumor progression model to study SFPQ-TFE3 translocated Renal Cell Carcinoma**
M. Ganpat, Princess Maxima Center, Utrecht, Netherlands

12:15 **Elucidating the oncogenic effect of BCOR-ITD in sarcoma**
M. O'Sullivan, University of Dublin, Trinity College, Ireland

Lunch Break & Poster Viewing

13:30 - 15:30 **New developments**
Chairs: D. Perotti & A. Verschuur

13:30 **Metronomic therapy and drug repositioning in solid tumours**
N. André, CRCM / AP-HM / AMU, Marseille

14:10 **Activated autologous T-cells against WT1/PRAME/Survivin in WT**
J. Dome, Children's National Hospital, Washington, DC

14:50 **Investigating structural associations of the lymphatic vasculature in Wilms tumor**
D. Jafree, UCL, London, UK

Coffee Break

16:00 - 18:00 **Clinical/Translational aspects**
Chairs: J. Dome, T. Chowdhury & R. Al-Saadi

16:00 **Treatment of relapsed renal tumors; knowledge gained from international/national molecular programmes & early phase trials**
J. Brok, Rigshospitalet, Copenhagen University Hospital, Denmark

16:30 **Creative clinical trial design**
M. C. Le Deley, Centre Oscar Lambret, Lille

17:00 **Clinical translation of a non-oncogene encoded vulnerability to Exportin 1 inhibition in pediatric renal tumors**
M. Ortiz, MSKCC, New York, USA

17:30 **Wrap up discussion - future directions & how to merge biology and clinics**
M. vd Heuvel, J. Geller, M. Gessler & V. Huff

18:00 **Farewell & Abstract Awards**

